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Abstract: We describe the effect of guanidinylation of the aminoglycoside moiety on 
acridine-neamine-containing ligands in the stem-loop structure located at the exon 10-5’-
intron junction of Tau pre-mRNA, an important regulatory element of tau gene alternative 
splicing. On the basis of dynamic combinatorial chemistry experiments, ligands that combine 
guanidinoneamine and two different acridines were synthesized and their RNA-binding 
properties were compared with those of their amino precursors. Fluorescence titration 
experiments and UV-monitored melting curves revealed that guanidinylation has a positive 
effect both on the binding affinity and specificity of the ligands for the stem-loop RNA, as 
well as on the stabilization of all RNA sequences evaluated, particularly some mutated 
sequences associated with the development of FTDP-17 tauopathy. However, this correlation 
between binding affinity and stabilization due to guanidinylation was only found in ligands 
containing a longer spacer between the acridine and guanidinoneamine moieties, since a 
shorter spacer produced the opposite effect (e.g. lower binding affinity and high 
destabilization). Furthermore, spectroscopic studies suggest that ligand binding does not 
significantly change the overall RNA structure upon binding (circular dichroism) and that the 
acridine moiety might intercalate near the bulged region of the stem-loop structure (UV-Vis 
and NMR spectroscopy). 
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Introduction 
RNA has enormous potential as a drug target since it is involved in many essential biological 
processes including the regulation of transcription and translation, as well as the control of 
gene expression. From a medicinal chemistry point of view, the ability of RNA to adopt 
complex three-dimensional architectures by folding local structures (e.g. hairpins, stem-loops, 
bulges, etc.) provides the oportunity to generate small molecules that could selectively bind 
and regulate its functions.1 Targeting such secondary structures found in miRNA precursors 
or in pre-mRNA, in most cases well-defined stem-loop structures, is particularly attractive 
since it would allow us to interfere with miRNA maturation and, for instance, to manipulate 
miRNA levels or to regulate alternative splicing, respectively.2 
Despite the enormous potential applications of RNA as a drug target, there are few small 
molecules with the optimal properties, e.g. high affinity and good specificity for a given RNA 
sequence.1,3 Today, the rational design of RNA ligands continues to be a difficult task mainly 
due to our poor understanding of RNA recognition principles and to the high conformational 
dynamics of this macromolecule, which hinders the prediction of tertiary structures and, for 
instance, the de novo design of RNA ligands.4 In addition, it is also important to confer RNA-
binding small molecules with pharmacological properties such as cell permeability to 
generate drug-like molecules.1b,5 Within this scenario, the combination of small molecules 
with known RNA-binding properties offers new opportunities for generating RNA ligands 
with an optimal balance between affinity and specificity.6  
We have recently described the usefulness of this approach in combination with dynamic 
combinatorial chemistry (DCC)7 to identify ligands for the stem-loop structure located at the 
exon 10-5’ intron junction of Tau pre-mRNA.8 In vitro and in vivo experiments had 
previously demonstrated that this stem-loop structure is an important regulatory element in 
pre-mRNA splicing since the extent of exon 10 inclusion is inversely proportional to its 
stability.9 The fact that mutations found in patients with frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17) diminish the stability of this stem-loop 
structure, led to the search for small molecules that selectively bind and stabilize to this 
structure, in particular the mutated variants.8,10 Such compounds are expected to restore the 
physiological balance of Tau protein isoforms generated upon alternative splicing of the tau 
gene and, consequently, the tauopathy to be treated.11  
In our previous work, selected compounds in DCC experiments showed some interesting 
properties, including high to medium binding affinities, moderate specificities and the ability 
to stabilize both the wt RNA and some mutated sequences.8 The most promising RNA-
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templated ligands combined a small aminoglycoside, neamine (Nea or Nea2 in Scheme 1), 
and heteroaromatic moieties such as azaquinolone or acridines (Azq, Acr1 or Acr2 in Scheme 
1). We hypothesize that such molecules interact with RNA via intercalation of the planar 
acridine moiety, probably in the bulge of the stem-loop structure,10c,12 as well as through 
electrostatic interactions and/or hydrogen bonds between the ammonium groups of the 
aminoglycoside and the RNA. This combination might be responsible for the stabilization 
ability but also for the moderate specificities of Tau acridine-neamine ligands. 
On the basis of these precedents, we wondered whether guanidinylation of the amino 
functions in the aminoglycoside moiety of acridine-neamine ligands would allow the affinity, 
specificity and stabilizing properties to be positively tuned. In fact, guanidinoglycosides,13 
like naturally occurring aminoglycosides, bind RNA preferentially over DNA and, more 
importantly, their high binding affinity and ability to discriminate between RNA molecules is 
substantially improved with respect to their aminoglycoside precursors through this chemical 
modification. For example, binding of guanidinoneomycin B to an RNA helix from the HIV-1 
frameshift site resulted in a considerable increase in the thermodynamic stability of the RNA 
target (the melting temperature was shifted by at least 10oC in the presence of 2 M urea).14 It 
is also important to consider that the introduction of guanidinium groups into the 
aminoglycoside scaffold will have a positive effect on the cell permeability of the ligands.15  
Here we report the synthesis of new Tau RNA ligands that combine guanidinoneamine and 
acridine moieties together with several biophysical studies on their interaction with RNA. The 
overall results show that guanidinylation has a positive effect on the binding affinity, 
specificity and ability of the ligands to stabilize RNA, including the mutated sequences. 
However, this effect was found to be highly dependent on the length of the spacer between 
both fragments since a shorter linker had a negative effect both on affinity and on stabilizing 
capacity.  
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Results and Discussion 
 
Exploring the effect of neamine guanidinylation using Dynamic Combinatorial 
Chemistry. Since a direct correlation between the ligand’s amplification in DCC experiments 
and their binding affinity and stabilizing properties has previously been observed,7,8 prior to 
synthesizing the guanidinylated analogues of acridine-neamine ligands, we decided to carry 
out a DCC experiment to gain some insight into the effect of guanidinylation on the RNA-
binding properties of such ligands.  
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Scheme 1 a) Sequences and secondary structure of wild-type (wt) and +3 and +14 mutated Tau stem-
loop RNAs. Exonic sequences are shown in capital letters and intronic sequences in lower case. 
Nucleotides involved in base pairs identified previously by NMR are connected by a dash.9a When 
required, biotin or fluorescein derivatization was performed at the 5’ end. The ends of the chains were 
modified with 2’-O-methylribonucleosides (denoted by an asterisk). b) Structure and peptide sequence 
of the building blocks used in the DCC experiments in our previous work8 and in the present study. 
 
For this purpose, we planned the synthesis of a new thiol-containing monomer, NeaG4 
(Scheme 2), which is the guanidinylated analogue of the neamine monomer containing the 
longer spacer between the aminoglycoside and the thiol group (Nea in Scheme 1). Nea was 
reacted with a large excess of N,N’-di-Boc-N”-triflylguanidine (20 mol eq), a powerful 
guanidinylating reagent usually employed in the preparation of guanidinoglycosides,16 in the 
presence of dithiothreitol (5 mol eq) and triethylamine (120 mol eq) at RT under an Ar 
atmosphere (Scheme 2). Once the reaction reached completion (about 4 days), the Boc-
protected guanidino derivative, (Boc)8NeaG4, was isolated by flash column chromatography 
and characterized by NMR and MS. After an acidic treatment with a TFA/DCM mixture (1:1) 
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containing TIS and EDT as cation scavengers, the desired NeaG4 derivative was identified as 
the major compound in the crude mixture by MS-HPLC. However, attempts to isolate it by 
reversed-phase HPLC were unsuccessful, possibly due to decomposition of the compound 
upon interaction with C18 stationary phase.  
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Scheme 2 Synthesis of the guanidinylated neamine monomers NeaG4 and NeaG4-SStBu. 
 
 
We then focused on the synthesis of the tert-butylsulfenyl-protected analogue, NeaG4-SStBu 
(Scheme 2), since this protecting group has been used in some DCC experiments involving 
disulphide exchange reactions.6d,17 First, reaction of (Boc)8NeaG4 with 
methoxycarbonylsulphenyl chloride in methanol afforded an activated species that upon 
treatment with tert-butylthiol in the presence of triethylamine gave the expected tert-butyl 
disulphide derivative, (Boc)8NeaG4-SS
t
Bu. Subsequent removal of the Boc-protecting groups 
with TFA in the presence of TIS afforded the desired monomer, NeaG4-SStBu, which was 
purified by reversed-phase HPLC and characterized by MS.  
 
The DCC experiment8 was carried out in aqueous solution with the biotinylated wt RNA 
target (25 µM) and the Nea, Nea2, NeaG4-SStBu, Acr2, Azq and TyrP monomers (4 mol eq 
each; see Scheme 1 for their structures) in Tris-HCl buffer (50 mM, pH 7.7) containing NaCl 
(100 mM) and EDTA (0.1 mM) at room temperature, under an air atmosphere without 
stirring. The RNA and the interacting ligands were separated from thiol monomers and other 
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non-interacting homo- and heterodimers with streptavidin anchored to magnetic beads using a 
magnet. The final step of the DCC experiment involved washing the beads with a hot (90ºC) 
acidic (0.1% TFA) aqueous solution to denature the RNA and release RNA-bound ligands, 
which were then identified and quantified by UV-MS-HPLC (Fig. 1).  
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Fig. 1 Results of the DCC experiment involving wt RNA and the Nea, Nea2, NeaG4-SStBu, Acr2, 
Azq and TyrP monomers. A) HPLC traces showing the composition of the DCL in the absence (left) 
and presence (right) of 5’-biotinylated wt RNA, after 1 week. B) Histograms showing the changes in 
DCL composition (left) and the percentage changes (% amplification) of each species (right) in the 
presence of the wt RNA. 
 
Comparison with the control experiment (RNA free exchange experiment) indicated the 
amplification of three disulphide heterodimers (Fig. 1): Acr2-Nea2 (≈800%), Acr2-Nea 
(≈250%) and Acr2-NeaG4 (≈450%). To our surprise, a large amount of the NeaG4-SStBu 
monomer remained unaltered after 1 week of incubation. This observation reveals that the 
disulphide exchange with the tert-butylsulphenyl protected monomer was not efficient under 
the air-mediated oxidation conditions employed for carrying out the DCC experiments. 
Despite the fact that a true thermodynamic equilibrium was not reached after 1 week of 
incubation, neither in the presence nor in the absence of RNA, two conclusions can be drawn 
from these results. First, as previously found, ligands incorporating the Acr2 fragment are 
amplified in much higher proportions than those containing other heteroaromatic moieties 
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such as Azq or Acr1.8 This confirms the high binding affinity of Acr2-containing ligands for 
Tau RNA, particularly when this acridine is combined with the neamine monomer that 
contains the shorter spacer between the thiol group and the aminoglycoside core (e.g. Acr2-
Nea2 amplification was three-fold higher than that of Acr2-Nea). Second, despite the fact that 
a large amount of the NeaG4-SStBu monomer did not participate in the disulphide exchange 
reactions, the amplification of the guanidinylated analogue of Acr2-Nea, namely Acr2-
NeaG4, was substantially higher, thereby suggesting a high binding affinity for wt RNA. 
Hence, we can conclude from these DCC results that replacement of the amino functions by 
guanidinium groups in the aminoglycoside moiety in ligands containing both acridine and 
neamine fragments might have a positive effect on their binding affinity. 
 
Synthesis of the guanidinylated ligands. On the basis of the DCC results, we planned the 
synthesis of the guanidinylated analogues of three acridine-neamine compounds previously 
identified as Tau RNA ligands: Acr1-Nea, Acr2-Nea and Acr2-Nea2.8 The structures of the 
parent ligands as well as of their guanidinylated analogues (Acr1-NeaG4, Acr2-NeaG4 and 
Acr2-Nea2G4, respectively) are shown in Scheme 3. For comparison purposes, the length and 
the type of linkage between the aminoglycoside and the acridine moieties were the same as 
those of the non-guanidinylated ligands (e.g. a disulphide linkage in Acr2-Nea2G4 and the 
thioether isostere (CH2-S) in Acr1-NeaG4 and Acr2-NeaG4).  
 
Synthesis of the Acr1-NeaG4 ligand was carried out by reaction between the thiol-containing 
Boc-protected guanidinoneamine and the acryloyl-derivatized acridine (Scheme 3) in the 
presence of a slight excess of sodium hydride (3 mol eq) for 4 h at RT under Ar. The Boc-
protected guanidinylated intermediate was treated with a 1:1 mixture of TFA/DCM in the 
presence of TIS and EDT to afford the desired Acr1-NeaG4 ligand after reversed-phase 
MPLC purification (two-step yield: 20%). Acr2-NeaG4 and Acr2-Nea2G4 were prepared by 
direct guanidinylation of their precursors, Acr2-Nea and Acr2-Nea2G4, respectively, 
following the procedure used for the synthesis of (Boc)8NeaG4. A 40-fold mol eq excess of 
N,N’-di-Boc-N”-triflylguanidine in the presence of NEt3 was used in both cases, and after 
acidic deprotection and HPLC purification, the desired ligands were obtained: Acr2-NeaG4 
(yield: 56%) and Acr2-Nea2G4 (yield: 20%). In conclusion, both the conjugate addition of 
(Boc)8NeaG4 over the acryloyl-derivatized acridine and the direct guanidinylation of the 
amino-precursors allow the synthesis of guanidinoneamine-acridine ligands with moderate 
yields. 
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Scheme 3 Synthesis (A) and schematic representation of the structure (B) of the guanidinylated and 
non-guanidinylated ligands. 
 
Binding affinities and specificities of the guanidinylated ligands. The binding affinity of 
the guanidinylated ligands was determined by fluorescence titration experiments.18 Wild-type 
RNA was labelled with fluorescein and, upon excitation at 490 nm, the fluorescence intensity 
was monitored as a function of the increase in the concentration of the ligand (typically from 
0.0005 to 3000 mol equivalents, depending on the ligand’s affinity). In all cases, a 
characteristic dose-dependent saturatable quenching in the fluorescence of RNA was observed 
(Fig. 2A), which was attributed to conformational changes in the RNA upon complexation 
with the ligands. The inherent fluorescence of the ligand was always subtracted from that of 
labelled RNA by repeating the full titration in the absence of RNA. Finally, EC50 values (the 
effective ligand concentration required for 50% RNA response) were obtained by fitting the 
data to a sigmoidal dose-response curve (Fig. 2B). 
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Fig. 2 (A) Fluorescence quenching of wt RNA labelled with fluorescein upon addition of increasing 
concentrations of Acr2-NeaG4. Measurements were performed with an RNA concentration of 0.25 
µM and ligand concentrations ranging from 0 (black) to 83.2 (blue) µM in 10 mM sodium phosphate 
buffer pH 6.8, 100 mM NaCl and 0.1 mM Na2EDTA. (B) Plot of the normalized fluorescence signal at 
517 nm against the log of Acr2-NeaG4 concentration. Fo is the initial fluorescence of fluorescein-
labelled RNA, Ff is the final fluorescence of the RNA and F is the observed fluorescence. 
 
The EC50 values of the three guanidinoneamine-acridine ligands together with those of their 
amino precursors are shown in Table 1. As a control, neamine and guanidinoneamine binding 
affinities for wt RNA were also determined. Consistent with our previous results,8 
guanidinylated ligands containing the Acr2 moiety showed higher binding affinities than the 
ligand containing Acr1 (e.g. EC50 = 2.4 µM for Acr2-NeaG4 vs. EC50 = 18.9 µM for Acr1-
NeaG4). As expected based on the DCC results, the guanidinylation of the four amino groups 
of neamine had a positive effect on the binding affinity of Acr1-Nea and Acr2-Nea. Indeed, 
the EC50 value for Acr1-NeaG4 was 1.5 times higher than for Acr1-Nea, and this effect was 
even higher (about 2.5 times) when comparing the values of Acr2-NeaG4 and Acr2-Nea. To 
our surprise, the EC50 value of the guanidinylated ligand containing the shorter spacer 
between acridine and neamine, Acr2-Nea2G4, was higher than that of Acr2-Nea2, which 
indicates that in this case guanidinylation had a negative influence on binding affinity. This 
effect was the opposite of that previously found with non-guanidinylated ligands, since the 
affinity was approximately three times higher for Acr2-Nea2 than for Acr2-Nea. As expected, 
the binding affinity of guanidinoneamine for wt RNA was substantially higher than that of 
neamine. The fact that this effect was stronger than that found in acridine-neamine ligands 
could be attributed to the high promiscuity of small amino- and guanidinoglycosides alone, 
which could have several binding sites in our RNA target. However, the effect of 
A B 
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guanidinylation on the binding affinity of ligands combining acridine and neamine may be 
strongly influenced by the existence of a preferred binding site for their non-guanidinylated 
precursors in the RNA target, probably driven in our case by intercalation of the 
heteroaromatic fragment.8,10,12 The opposite effect of guanidinylation on Acr2-Nea and Acr2-
Nea2 suggests that the introduction of four guanidinium groups into the ligand with the 
shortest spacer might generate sterical hindrance, leading to a loss of affinity. However, the 
longer distance between the two fragments in Acr1-NeaG4 or in Acr2-NeaG4 would not 
impede the optimal accommodation of acridine and guanidinoneamine in the stem-loop RNA 
structure, leading to an increase in affinity due to the positive effect of the guanidium groups.  
 
Table 1. Binding of the ligands to wt RNA in the absence or in the presence of a tRNA competitor. 
 
 
 
 
 
 
[a] All fluorescence measurements (0.25 µM RNA) were performed in 10 mM sodium phosphate 
buffer pH 6.8, 100 mM NaCl and 0.1 mM Na2EDTA. [b] Measured in the presence of a 30-fold 
nucleotide excess of a mixture of tRNA (tRNAmix).  
Fluorescence binding assays were repeated in the presence of a large excess (30-fold 
nucleotide excess) of a tRNAmix from baker’s yeast that contains a mixture of pre- and mature 
tRNAs. These competitive experiments allow the specificity of the ligands to be determined, 
according to the ratio between the EC50 value in the presence of the competitor and the EC50 
value in the absence of the competitor.18b,19 Again, the specificity of the guanidinylated 
ligands was shown to be highly dependent both on the nature of the acridine building block 
and on the distance of the spacer between the acridine and the guanidinoneamine units. In the 
presence of the competitor, the EC50 values of Acr2-NeaG4 and Acr2-Nea2G4 for Tau RNA 
were increased by 10-fold and 14-fold, respectively, whereas that of Acr1-NeaG4 was only 
increased by 2.4-fold. Hence, the Acr1 moiety confers higher specificity to acridine-
guanidinoneamine-containing ligands in comparison with Acr2. This behaviour was similar to 
Ligand 
EC50 
(µM)[a] 
EC50 (µM) 
+tRNA[b] 
EC50+tRNA  
/ EC50  
Neamine 3100 nd nd 
Guanidinoneamine 830 nd nd 
Acr1-Nea 28.6 112.2 3.9 
Acr1-NeaG4 18.9 45.5 2.4 
Acr2-Nea 5.9 63.1 10.7 
Acr2-NeaG4 2.4 24.9 10.4 
Acr2-Nea2 2.1 47.0 22.4 
Acr2-Nea2G4 3.6 50.9 14.1 
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that shown by non-guanidinylated ligands, since Acr1-Nea was more specific for Tau RNA 
than Acr2-Nea/Nea2. Interestingly, guanidinylation of Acr1-Nea and Acr2-Nea2 had a 
positive effect on the specificity of both ligands since the specificity ratio of Acr1-NeaG4 and 
Acr2-Nea2G4 was reduced about 1.5-fold when compared with that of their amino precursors. 
However, a similar specificity ratio was obtained for Acr2-Nea and Acr2-NeaG4. As shown 
in Table 1, the specificity ratio for Acr2-Nea2G4 was higher than that of Acr2-NeaG4, 
showing a similar trend to their non-guanidinylated precursors, Acr2-Nea and Acr2-Nea2. 
The overall results indicate that guanidinylation of acridine-neamine ligands has a positive 
(Acr1-NeaG4 and Acr2-Nea2G4) or minimal (Acr2-NeaG4) effect on their specificity for Tau 
RNA. In addition, a longer spacer always confers higher specificity to Acr2-containing 
ligands, either non-guanidinylated, as previously reported (Acr2-Nea vs. Acr2-Nea2)8 or 
guanidinylated (Acr2-NeaG4 vs. Acr2-Nea2G4), thus differing from the trend found in 
acridine-neomycin ligands with the HIV-1 RRE RNA target.19b,20 It is interesting that no 
correlation between affinity and specificity was found in guanidinylated Acr2-containing 
ligands, since the ligand with the highest affinity (Acr2-NeaG4) was also the most specific. 
This trend contrasts with that found in their non-guanidinylated precursors, in which there 
was an inverse correlation between the two parameters. 
Effect of the guanidinylated ligands on the thermal stability of Tau RNA targets. Our 
next objective was to evaluate the ability of the guanidinylated ligands to stabilize Tau RNA 
targets, in particular some of the mutated sequences associated with FTDP-17 development. 
The thermal stability of the stem-loop structures (wt and +3 and +14 mutants) was determined 
by UV melting experiments by monitoring the absorbance as a function of temperature. The 
midpoint of the transition (see Figures S1-S3 in the Supporting Information) is referred to as 
the melting temperature (Tm), which is indicative of the thermal stability of the RNA 
secondary structure. As shown in Table 2, ∆Tm values indicate the effect of the ligands on the 
thermal stability of RNA upon complexation, whereas ∆TmG indicate the effect of 
guanidinylation compared with that of the parent non-guanidinylated ligand. 
As with non guanidinylated ligands, replacement of Acr1 by Acr2 in the acridine-
guanidinoneamine ligands with the longest spacer caused an increase in the Tm value of all 
RNAs. This increase was particularly high for the +3 (∆Tm = +5.9oC with Acr2-NeaG4 vs. 
∆Tm = +2.9oC with Acr1-NeaG4) and the +14 mutants (∆Tm = +2.6oC with Acr2-NeaG4 vs. 
∆Tm = +1.2oC with Acr1-NeaG4). As shown in Table 2, guanidinylation of Acr1-Nea or 
Acr2-Nea always had a positive effect on the thermal stability of all RNAs upon 
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complexation with the ligands, particularly with the +3 mutant (∆TmG = +1.7oC for Acr1-
NeaG4 and ∆TmG = +3.1oC for Acr2-NeaG4). The fact that no significant additional 
stabilization was provided by guanidinoneamine compared to neamine suggests that both 
aminoglycosides might interact with Tau RNA through the major groove or with the loop. 
However, the interaction of the heteroaromatic moiety of the acridine-guanidinoneamine 
ligands within the duplex of the stem-loop structure (see below) through an intercalative or 
stacking mechanism might be responsible for the optimal allocation of the guanidinoneamine 
fragment, thereby causing significant changes in RNA Tm values. To our surprise, the Tm 
values of all RNAs were clearly decreased (e.g. ∆TmG = -2.8oC with the +3 mutant, see Table 
2) in the presence of the guanidinylated ligand with the shortest spacer, Acr2-Nea2G4. In 
some cases, the ability of this ligand to stabilize wt RNA or the mutant sequences was even 
lower than that of the non-guanidinylated ligands with the longest spacer, Acr1-Nea or Acr2-
Nea. 
 
Taken together, these results show a good correlation between binding affinities of the 
guanidinylated ligands and their ability to stabilize target Tau RNAs. Indeed, the Tm values of 
all RNAs were clearly increased in the presence of the guanidinylated ligands (Acr1-NeaG4 
or Acr2-NeaG4) that had shown higher binding affinities than their non-guanidinylated 
precursors (Acr1-Nea and Acr2-Nea, respectively). The increase both in the affinity and 
stabilizing ability of such ligands can be explained by the generation of a strong synergism 
upon linking guanidineamine and acridine through a long spacer.19b,21 The length and 
flexibility provided by the spacer would favour the establishment of stabilizing interactions 
such as hydrogen bonds and/or electrostatic interactions between guanidinium groups and 
RNA, as well as the optimal orientation of the heteroaromatic moieties. Interestingly, 
guanidinylation of the ligand with the shortest spacer, Acr2-Nea2, led to a substantial 
decrease both in the binding affinity and in its capacity to stabilize RNAs, particularly the +3 
and +14 mutants. As previously mentioned, this may be due to the proximity of the two 
fragments in Acr2-Nea2G4, which could hinder not only the most favorable interactions of 
the guanidinium groups with RNA but also the proper orientation of the acridine moiety in the 
stem-loop structure via intercalation or stacking. The loss in stabilization capacity of this 
ligand compared to its amino precursor supports the second explanation. All these 
observations highlight the importance of the spacer linking two entities in modularly 
assembled RNA ligands, since their relative orientation determines their RNA binding 
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properties. Since the optimal molecular arrangement of a ligand can also be dramatically 
perturbed by guanidinylation, it is important to carefully select the amino groups to be 
guanidinylated since otherwise this chemical modification could negatively affect RNA-
binding properties. 
 
Table 2. Melting temperatures (Tm) for the complexation of ligands with target RNAs (1 µM both in 
RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl and 0.1 mM 
Na2EDTA).  
 
 
 
 
 
 
 
 
 
 
[a] ∆Tm= (Tm of the RNA in the presence of ligand) – (Tm of RNA alone).  
[b] ∆TmG= (Tm of the RNA in the presence of the guanidinylated ligand) – (Tm of the RNA  in 
the presence of the parent non-guanidinylated ligand). 
 
 
Spectroscopic studies of the complexes formed between Tau RNA and the 
guanidinylated ligands. The overall results indicate that guanidinylated ligands with the 
longest spacer between the acridine moieties and neamine, Acr1-NeaG4 and Acr2-NeaG4, 
showed an adequate balance between affinity, specificity and RNA stabilizing properties. 
Hence, we wanted to gain some insight into the effect of this chemical modification on the 
structure of the RNA-ligand complexes in comparison with that of their non-guanidinylated 
precursors, Acr1-Nea and Acr2-Nea.8 
First, Acr1-NeaG4 and Acr2-NeaG4 were titrated with increasing quantities of wt Tau RNA 
to determine whether the acridine moiety has an active role in the interaction with RNA. 
Consistent with our previous results with non-guanidinylated ligands, strong hypochromism 
(30-40%) was observed in the UV-Vis spectra of both ligands in the first stage of the titration 
 Tm wt ∆Tm[a] ∆TmG[b] Tm +3 ∆Tm[a] ∆TmG[b] Tm +14 ∆Tm[a] ∆TmG[b] 
No ligand 66.4 - - 50.8 - - 54.0 - - 
Neamine 67.6 +1.2 - 51.8 +1.0 - 54.4 +0.4 - 
Guanidinoneamine 67.7 +1.3 +0.1 52.2 +1.4 +0.4 54.5 +0.5 +0.1 
Acr1-Nea 67.1 +0.7 - 52.0 +1.2 - 54.1 +0.1 - 
Acr1-NeaG4 68.0 +1.6 +0.9 53.7 +2.9 +1.7 55.2 +1.2 +1.1 
Acr2-Nea 68.5 +2.1 - 53.6 +2.8 - 56.0 +2.0 - 
Acr2-NeaG4 68.7 +2.3 +0.2 56.7 +5.9 +3.1 56.6 +2.6 +0.6 
Acr2-Nea2 68.8 +2.4 - 56.5 +5.7 - 57.2 +3.2 - 
Acr2-Nea2G4 67.2 +0.8 -1.6 53.7 +2.9 -2.8 54.5 +0.5 -2.7 
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(0.2 mol eq of RNA). In addition, both ligands exhibited a shift to higher wavelengths 
although this effect was smaller for Acr1-NeaG4 (a 2 nm redshift of the 360 nm band of the 
free ligand) than for Acr2-NeaG4 (a 7 and 9 nm redshift of the 423 and 444 nm bands of the 
free ligand, respectively; see Fig. 3).8 Such bathochromic effects are commonly observed for 
DNA or RNA intercalators and suggest that the acridine moiety in both ligands binds the 
stem-loop structure of Tau RNA through intercalation or stacks with base-pair nucleobases. 
Interestingly, in the second stage of the titration, the intensities of the two new peaks of the 
Acr2-NeaG4 ligand (430 and 453 nm) increased gradually until saturation was reached. This 
two-stage binding mode was found by Varani et al. for the mithoxantrone ligand,10c and might 
suggest the allocation of the ligand to a preferred binding site. The fact that this behaviour 
was not observed with Acr1-NeaG4 might be attributed to the lower binding affinity of this 
ligand compared with that of the Acr2-containing ligand.  
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Fig. 3 UV-Vis titration of the Acr1-NeaG4 (left) and Acr2-NeaG4 (right) ligands (50 µM) with 
increasing amounts of wt RNA (0-2 eq) in a 10 mM sodium phosphate buffer, pH 6.8, containing 100 
mM NaCl and 0.1 mM Na2EDTA. 
 
NMR spectroscopy was used to gain an insight into the effect of guanidinylation on the 
binding mode of acridine-neamine containing ligands. The effect of ligand addition on the 
imino region of the NMR spectra of wt RNA was studied using Acr1-Nea and Acr1-NeaG4. 
As shown in Fig. S4 (see the Supporting Information), the addition of Acr1-Nea caused a 
general line broadening of all signals but no significant changes in the chemical shifts. These 
effects on the NMR spectra indicate that the ligand binds the RNA with intermediate 
exchange kinetics, which is consistent with its moderate binding affinity. However, addition 
of the guanidinylated analogue of this ligand, Acr1-NeaG4, provoked less broadening at the 
same RNA/ligand ratio as well as some minor changes in the chemical shifts of some imino 
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protons of the RNA. This effect was particularly significant for the imino resonance of G+1 
(δ: 12.65 ppm), which was shifted in the RNA-ligand complex (δ: 12.53 ppm). Further 
addition of the ligand caused a pronounced broadening of all signals in the NMR spectra.  
Taken together, these effects on the NMR spectra and the UV-Vis spectroscopy results lead 
us to suggest that the heteroaromatic moiety of acridine-guanidinoneamine ligands may 
intercalate or stack around the bulged adenine. This binding mode is consistent with results 
reported recently by Varani et al. for the Tau-RNA-mitoxantrone complex.10c Moreover, 
changes in the chemical shifts of the imino resonances in the upper helical region (e.g., G+1 
and U+2) may be a consequence of strong binding of the guanidinoglycoside moiety of Acr1-
NeaG4 in comparison with that of neamine in Acr1-Nea.  
 
Finally, circular dichroism was used to study the conformation of the RNA-ligand complexes. 
CD spectra of wt and of the +3 mutant were recorded in the presence of 1 mol eq of the most 
representative guanidinylated ligands, Acr1-NeaG4 and Acr2-NeaG4. As shown in Fig. 4, the 
typical spectra of A-form RNA were obtained for wt and +3 sequences alone, with a strong 
negative band at 211 nm, two small bands at 223 and 234 nm, and a strong positive band at 
268 nm; the presence of a shoulder at 280 nm is a characteristic feature of duplexes capped 
with a loop structure.22 Upon binding of Acr1-NeaG4 or Acr2-NeaG4, the CD spectra of the 
complexes were essentially superimposable on that of wt RNA (Fig. 4A) which indicates that 
the conformation of the stem-loop structure had not been substantially altered. However, the 
effect of the ligands on the conformation of the +3 mutated RNA was more substantial 
possibly due to the intrinsically lower thermodynamic stability compared with that of wt. As 
shown in Fig. 4B, the alterations induced by the ligands in duplex CD bands included a 
decrease in the intensity of the positive band at 234 nm and a concomitant increase in the 
ellipticity of the positive band at 268 nm, together with a small wavelength shift (a 3 nm blue-
shift for Acr1-Nea/NeaG4 and a 1 nm red-shift for Acr2-Nea/NeaG4). The overall changes 
are also consistent with a small binding-induced change in the conformation of the +3 mutant 
sequence, although typical A-spectra were maintained in all cases, this being important for the 
recognition of the ligand-stabilized stem-loop by the splicing regulatory machinery. It is 
particularly interesting to note that ligands with higher binding affinities and stabilizing 
properties (e.g. Acr2-NeaG4) induced higher alterations in the CD spectra of RNA upon 
binding. 
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Fig. 4 Overlay of CD spectra for the wt (left) and +3 (right) mutated RNA and its ligand complexes at 
a [ligand]/[RNA] ratio of 1.0. 
 
Conclusions 
 
In summary, we have shown that guanidinylation of the aminoglycoside moiety of ligands 
combining neamine and acridine strongly influences their RNA-binding properties (affinity, 
specificity and stabilizing ability). The distance between the two fragments in our modularly 
assembled ligands is a key parameter since it influences the effect of guanidinylation on these 
properties, either positively or negatively. For example, guanidinylation has a positive effect 
on acridine-neamine ligands containing the longest spacer since higher binding affinities for 
Tau RNA were determined by fluorimetry (e.g. EC50 = 2.4 µM for Acr2-NeaG4 vs. EC50 = 
5.9 µM for Acr2-Nea). However, guanidinylation of the analogous ligand containing the 
shortest spacer resulted in a reduced binding affinity for Tau RNA (e.g. EC50 = 3.6 µM for 
Acr2-Nea2G4 vs. EC50 = 2.1 µM for Acr2-Nea2). The same correlation was observed in the 
ability of such ligands to stabilize Tau RNA, particularly the +3 and +14 mutated sequences 
associated with the development of FTDP-17. For example, Acr2-NeaG4 stabilized the +3 
mutant by 5.9 ºC whereas Acr2-Nea2G4 only increased the Tm value by 2.9 ºC. Hence, 
guanidinium modification in ligands with the longest spacer substantially increased the 
stability of the target RNA (+3.1ºC) whereas the guanidinium-containing derivative with the 
shortest spacer showed less thermal stabilization (-2.8ºC) than the parent non-guanidinylated 
ligand. These results might be attributed to the generation of some sterical hindrance by the 
four guanidinium groups when acridine and guanidinoneamine are closely attached, which 
may make it difficult for both entities of the ligand to adopt the optimal binding site in RNA. 
In addition, competition studies performed in the presence of an excess of tRNA revealed that 
guanidinylation of the aminoglycoside fragment in Tau acridine-neamine ligands has, in 
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general, a positive effect on their specificity. Furthermore, CD spectroscopy indicated that 
guanidinylated ligands do not significantly change the overall structure of the stem-loop 
RNA, whereas UV-Vis and NMR spectroscopy titration experiments suggested that the 
heteroaromatic moiety intercalates or stacks, probably near the bulging adenine of the stem-
loop structure.  
It is also important to mention that there was a correlation between the RNA-binding 
properties of the ligands and the results of dynamic combinatorial chemistry experiments, 
thereby confirming the usefulness of this methodology for identifying ligands for a particular 
RNA target. The identification of acridine-guanidinoneamine ligands that bind and stabilize 
the mutated sequences of Tau exon 10 splicing regulatory element RNA may open up 
possibilities for the generation of small molecules for the treatment of frontotemporal 
dementias such as FTDP-17 by restoring the physiological balance of Tau isoforms. 
Moreover, the guanidinium groups incorporated into such ligands are expected to improve 
their pharmacological properties, such as permeability through cell membranes, a key issue 
for conferring drug-like properties to RNA ligands, although this chemical modification does 
not guarantee their ability to cross the blood-brain barrier. These compounds may also be 
attractive for studying alternative splicing and its regulation by RNA secondary structures. 
Current efforts are aimed at improving the affinity and specificity of such Tau RNA ligands 
by modulating the heteroaromatic and aminoglycoside moieties. 
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Experimental Section 
Materials and Methods. Unless otherwise stated, common chemicals and solvents (HPLC 
grade or reagent grade quality) were purchased from commercial sources and used without 
further purification. Fmoc-protected amino acids, resins and coupling reagents for solid phase 
synthesis were obtained from Novabiochem, Bachem or Iris Biotech. RNA, biotin and 
fluoresceine phosphoramidites, solid-supports, reagents and solvents for oligoribonucleotide 
synthesis were purchased from Glen Research or Link Technologies. 
RNase-free reagents, solutions and materials were used when manipulating deprotected 
oligoribonucleotides. RNase-free water was obtained directly from a Milli-Q system equipped 
with a 5000-Da ultrafiltration cartridge.  
Solid-phase syntheses were performed manually in a polypropylene syringe fitted with a 
polyethylene disc (building blocks and peptides), or using the ABI3400 automatic DNA 
synthesizer from Applied Biosystems (oligonucleotides). 
Thin-layer chromatography analyses (TLC) were conducted on aluminium plates coated with 
a 0.2 mm thick layer of silica gel 60 F254 (Merck). Purification by flash column 
chromatography was carried out using silica gel 60 (230-400 mesh).  
Reversed-phase high-performance liquid chromatography (HPLC) analyses were carried out 
on Kromasil or Nucleosil C18 columns (250x4.6 mm, 10 or 5 µm, flow rate: 1 mL/min), using 
linear gradients of 0.045% TFA in H2O and 0.036% TFA in ACN for peptides, monomers and 
ligands, and 0.1 M aqueous NH4HCO3, and a 1:1 mixture of 0.1 M aqueous NH4HCO3 and 
ACN for RNA. In some cases, purification was carried out using the same analytical column.  
A [Vydac C18]-filled glass column (22x2 cm, 15-20 µm, 300 Å) was used for medium 
pressure liquid chromatography (MPLC), using aqueous and ACN solutions containing 0.05% 
TFA (flow rate: 2-3 mL/min). Elution was carried out by connecting a piston pump to the 
mixing chamber of a gradient-forming device and to the top of the glass column. The mixing 
chamber of the gradient-forming device was the flask containing solvent A, which was 
connected through a stopcock to the flask containing solvent B. The bottom of the preparative 
column was connected to an automatic fraction collector through a UV/Vis detector which 
was also connected to a chart recorder using the appropriate ports. Equilibration of the 
column was carried out with 200 mL of solvent A, and 600 mL of each mobile phase was 
introduced in the appropriate compartments of the gradient-forming device. 
NMR spectra were recorded at 25ºC on Varian spectrometers (400 or 500 MHz) using 
deuterated solvents. Tetramethylsilane (TMS) was used as an internal reference (0 ppm) for 
1H spectra recorded in CDCl3 and the residual signal of the solvent (77.16 ppm) for 
13C 
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spectra. For CD3OD or D2O, the residual signal of the solvent was used as a reference. 
Chemical shifts are reported in part per million (ppm) in the δ scale, coupling constants in Hz 
and multiplicity as follows: s (singlet), d (doublet), t (triplet), q (quadruplet), qt (quintuplet), 
m (multiplet), dd (doublet of doublets), td (doublet of triplets), ddd (doublet of doublet of 
doublets), br (broad signal). 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectra were 
recorded on a Voyager-DETMRP spectrometer (Applied Biosystems) both in positive (2,4-
dihidroxybenzoic acid matrix) or negative mode (2,4,6-trihidroxyacetophenone matrix with 
ammonium citrate as an additive). Electrospray ionization mass spectra (ESI-MS) were 
recorded on a Micromass ZQ instrument with single quadrupole detector coupled to an 
HPLC, and high-resolution (HR) ESI-MS on an Agilent 1100 LC/MS-TOF instrument. 
 
General procedure for the RNA-templated DCC experiments. DCC experiments were 
carried out as previously described.8 Briefly, 6 nmol of biotinylated wt RNA were annealed in 
240 µL of buffer (50 mM Tris-HCl, pH 7.7, 100 mM NaCl and 0.1 mM Na2EDTA) by 
heating to 90 ºC for 5 min and then slowly cooling to room temperature. After overnight 
incubation at RT, the solutions were stored at 4 ºC. Then, annealed biotinylated RNA was 
added to an Eppendorf tube containing the quantified (Ellman’s test) thiol building blocks, 
and the resulting mixture left to stand at RT under air without stirring. At the desired time, the 
disulfide exchange was stopped by the addition of 45-70 µL of 0.1 % TFA solution in water 
(final pH ∼ 5-6).  
The biotinylated RNA and the binding ligands were isolated with streptavidin-coated 
magnetic beads (Biomag Streptavidin, 5 mg mL-1 suspension, Qiagen). A magnet was used in 
all washing procedures to retain the beads in the tube while the supernatant was pipetted off. 
First, the beads (500 µL of suspension for each DCL aliquot) were separated from the 
commercial buffer solution and washed with an acidic buffer (3 x 500 µL of 50 mM Tris-HCl, 
pH 5.8, 100 mM NaCl and 0.1 mM Na2EDTA). DCL aliquots were added to the washed 
beads and incubated at room temperature. After 20 min, the beads were retained in the vessel 
using the magnet and the supernatant solution was pipetted off again. Then, the beads were 
treated to remove the non-interacting ligands and building blocks (3 x 200 µL of 50 mM Tris-
HCl, pH 5.8, 100 mM NaCl and 0.1 mM Na2EDTA). Finally, the beads were washed with a 
hot solution of 0.1% TFA in H2O in order to liberate RNA-binding ligands (3 x 200 µL, 
incubation at 90 ºC for 10 min). The solutions were combined and evaporated in a Speed-Vac. 
The final residue was dissolved in 0.1 % TFA in H2O and analysed by UV-MS HPLC. 
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Elution was performed on a GraceSmart C18 column (150 x 2.1 mm, 5 µm, flow rate: 0.25 mL 
min-1) with linear gradients of H2O and ACN containing both solvents either 0.1% formic 
acid or 0.1 % formic acid and 0.01 % TFA to avoid the overlapping of some peaks and to 
allow a more accurate integration. All peak areas of the HPLC traces were integrated and 
normalized taking into account the extinction coefficient of each compound at the detection 
wavelength (260 nm).8  
 
Synthesis of the guanidinylated neamine monomer NeaG4-SS
t
Bu. (Boc)8NeaG4: 
Neamine thiol monomer (Nea) (50 mg, 0.114 mmol) was dissolved in a 5:3 mixture of 
MeOH/CHCl3 5:3 (5 mL). Then, 1,3-di-Boc-2-(trifluoromethylsulfonyl)guanidine (892 mg, 
2.28 mmol), dithiotreitol (90 mg, 0.59 mmol) and triethylamine (640 µL, 13.68 mmol) were 
added sequentially. After stirring for 4 days at RT under Ar, the reaction mixture was diluted 
with CHCl3 (100 mL) and washed with a 0.1 M aqueous solution of citric acid (2 x 50 mL) 
and with brine (50 mL). The organic phase was taken up and dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to dryness. After flash column chromatography (gradient: 
0-4 % MeOH in DCM), the desired product was obtained as white solid (30 mg, 18 %). Rf (4 
% MeOH en DCM): 0.61; 1H NMR (400 MHz, CD3OD) δ (ppm): 5.67 (1H, d, J=4), 4.54 
(1H, ddd, J=11, J’=6.8, J’’=4.4), 4.36 (1H, dd, J=10.6, J’=4), 4.12 (1H, ddd, J=13.2, 
J’=7.4, J’’=4.8), 3.95 (1H, dt, J=8.4, J’=6.4), 3.83 (1H, td, J=9.2, J’=2.4), 3.78 (1H, td, 
J=9.2, J’=2.4), 3.70 (1H, m), 3.55 (1H, dd, J=10.8, J’=9), 3.47 (1H, dt, J=11.2, J’=5.8), 3.40 
(2H, m), 3.26 (1H, t, J=9.2), 2.64 (1H, dd, J=6.8, J’=1.2), 2.48 (2H, t, J=7.2), 2.24 (1H, dt, 
J=12.4, J’=4.4), 1.45-1.70 (79H, m), 1.35 (2H, q, J=7.4); 13C NMR (100 MHz, CD3OD) δ 
(ppm): 164.7, 164.5, 164.4, 164.3, 158.3, 158.0, 157.6, 157.6, 154.7, 154.5, 154.2, 154.0, 
98.0, 87.7, 84.8, 84.8, 84.7, 84.6, 80.6, 80.6, 80.6, 80.5, 78.4, 77.0, 74.9, 73.4, 73.0, 71.9, 
55.4, 52.2, 50.3, 44.3, 35.5, 35.4, 31.2, 29.4, 28.8-28.3, 26.8, 24.9; ESI-MS, positive mode: 
m/z 1408.0 (calcd mass for C62H111N12O22S [M+H]
+: 1407.77). 
(Boc)8NeaG4-SS
t
Bu: A solution of methoxycarbonylsulfenyl chloride (2.8 µL, 31.2 µmol) 
and NEt3 (4.3 µL, 31.2 µmol) in MeOH (0.3 mL) was added dropwise and under Ar to a 
solution of (Boc)8NeaG4 (22 mg, 15.6 µmol) in a 1:1 mixture of MeOH/CHCl3 (0.5 mL) at 0 
°C. The reaction mixture was continuously stirred at 0 °C under Ar and additional aliquots of 
methoxycarbonylsulfenyl chloride (2.8 µL, 31.2 µmol) and NEt3 (4.3 µL, 31.2 µmol) in 
MeOH (0.3 mL) were added until no starting product was detected by MALDI-TOF MS 
analysis. Then, the mixture was concentrated in vacuo. The remaining crude was dissolved in 
MeOH (0.3 mL) and the solution was added, dropwise and under Ar, to a solution of 2-
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methyl-2-propanethiol (18 µL, 0.156 mmol) and NEt3 (21 µL, 0.156 mmol) in MeOH (0.5 
mL). After stirring for 1 h at RT under Ar, the solvent was evaporated in vacuo and the 
residue was dissolved in DCM (10 mL). The organic phase was washed with 10% aqueous 
citric acid solution (3 x 10 mL) and brine (10 mL), dried over anhydrous MgSO4 and filtered, 
and the solvent was removed in vacuo. Purification by silica gel flash column 
chromatography (gradient: 0-2 % of MeOH in DCM) afforded the desired product as a white 
solid (8 mg, 35 %). Rf (2 % MeOH in DCM): 0.19; 
1H-NMR (400 MHz, CDCl3) δ (ppm): 
11.63 (1H, s), 11.52 (1H, s), 11.42 (1H, s), 11.37 (1H, s), 8.85 (1H, br s), 8.51 (1H, br t, 
J=5.6), 8.46 (1H, br s), 8.17 (1H, d, J=8.4), 7.53 (1H, d, J=8.4), 7.37 (1H, d, J=9.2), 7.12 
(1H, m), 5.54 (1H, d, J=3.6), 4.40 (2H, m), 4.20 (1H, m), 3.98 (2H, m), 3.77 (1H, t, J=10.0), 
3.67-3.54 (4H, m), 3.47 (2H, m), 3.31 (2H, m), 2.66 (1H, t, J=7.6), 2.34 (1H, dt, J=13.2, 
J’=4.4), 1.62-1.37 (90H, m); ESI-MS, positive mode: m/z 1495.9 [M+H]+; MALDI-TOF-MS, 
positive mode: m/z 1496.1 (calcd mass for C66H119N12O22S2 [M+H]
+: 1495.80).  
NeaG4-SS
t
Bu. Neamine derivative (Boc)8NeaG4-SS
t
Bu (8 mg, 5.35 µmol) was dissolved in 
a TFA/DCM mixture (2 mL, 1:1) containing 2.5 % of TIS, and the mixture was stirred at RT 
for 2 h. Then, the solution was diluted with toluene (3 mL) and evaporated in vacuo. The 
residue was dissolved in Milli-Q H2O (10 mL) and the aqueous phase was washed with DCM 
(2 x 10 mL), diethyl ether (10 mL) and lyophilized to provide a white solid. Purification was 
carried out by MPLC eluting with a gradient from 0 to 100 % of B (A: 0.05 % TFA in H2O, 
B: 0.05 % TFA in H2O/ACN 65:35, 600 mL each solvent). Pure fractions by ESI-MS HPLC 
(5 min isocratic elution with A and linear gradient from 0 to 70 % B in 25 min; A: 0.1 % 
formic acid in H2O and B: 0.1 % formic acid in ACN; Rt= 13.5 min) were combined and 
lyophilized, providing the TFA salt of the desired product NeaG4-SStBu as a white foam 
(0.54 µmol, 12 %). ESI-MS, positive mode: m/z 695.43 (calcd mass for C26H55N12O6S2 
[M+H]+: 695.38), m/z 348.14 (calcd mass for C26H56N12O6S2 [M+2H]
2+: 348.19); MALDI-
TOF-MS, positive mode: m/z 695.38 [M+H]+). 
 
Synthesis of the guanidinylated ligands. N-(3-Acrylamidopropyl)acridine-9-carboxamide: 
N-(3-Aminopropyl)acridine-9-carboxamide8 (300 mg, 0.76 mmol) and NaHCO3 (256 mg, 
3.05 mmol) were dissolved in a 1:1 mixture of H2O/dioxane (30 mL) and cooled to 0 ºC. 
Then, a solution of acryloyl chloride (230 µL, 2.28 mmol) in dioxane (2 mL) was added 
dropwise and the resulting reaction mixture was stirred at 0 ºC for 20 min. Again, acryloyl 
chloride (230 µL, 2.28 mmol) in dioxane (2 mL) and NaHCO3 (200 mg, 2.38 mmol) were 
added and the mixture was stirred at 0 ºC for additional 20 min, After evaporation in vacuo, 
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purification by silica gel flash column chromatography (gradient: 0-3 % of MeOH in DCM) 
afforded the desired product (57 mg, 22 %). Rf (10% MeOH en DCM): 0.51; 
1H-NMR (400 
MHz, CD3OD) δ (ppm): 8.20 (2H, d, J=8.8), 8.10 (2H, d, J=8.8), 7.89 (2H, ddd, J=8.8, 
J’=6.8, J’’=1.2), 7.69 (2H, ddd, J=8.8, J’=6.8, J’=1.2), 6.28 (1H, dd, J=17.2, J=9.0), 6.22 
(1H, dd, J=17.2, J=3.0), 5.67 (1H, dd, J=9.0, J=3.0), 3.69 (2H, t, J=6.8), 3.46 (2H, t, J=6.8), 
2.00 (2H, q, J=6.8); 13C-NMR (100 MHz, CD3OD) δ (ppm): 169.3, 168.4, 149.6, 143.8, 
132.3, 132.0, 129.6, 128.3, 126.8, 126.6, 123.7, 38.7, 38.2, 30.3; ESI-MS, positive mode: m/z 
334.1 (calcd mass for C20H20N3O2 [M+H]
+: 334.15).  
Acr1-NeaG4: N-(3-acrylamidopropyl)acridine-9-carboxamide (10 mg, 30 µmol), 
(Boc)8NeaG4 (50 mg, 36 µmol) and NaH (3.6 mg, 90 µmol, 60 % dispersion in mineral oil) 
were dissolved in anhydrous DMF (5 mL) and stirred at RT for 4 h under Ar. Then, the 
mixture was diluted with water (1 mL) and evaporated to dryness. After several co-
evaporations from acetonitrile, purification by flash chromatography (gradient: 0-10 % of 
MeOH in DCM) afforded the desired Boc-protected intermediate (42 mg crude). 
The product was dissolved in a 1:1 mixture of TFA/DCM (2 mL) and TIS (80 µL, 390 µmol) 
and ethanedithiol (80 µL, 990 µmol) were added. After stirring at RT for 3 h under Ar, the 
mixture was diluted with toluene (2 mL) and evaporated in vacuo. After two co-evaporations 
from toluene, the residue was dissolved in Milli-Q H2O (20 mL) and the aqueous phase was 
washed with DCM (2 x 20 mL), diethyl ether (20 mL) and lyophilized to provide a white 
solid. Purification was carried out by MPLC eluting with a gradient from 0 to 100 % of B (A: 
0.05 % TFA in H2O/ACN 95:5, B: 0.05 % TFA in H2O/ACN 70:30, 600 mL each solvent). 
Pure fractions by analytical HPLC (linear gradient from 0 to 50 % B in 30 min; A: 0.045 % 
TFA in H2O and B: 0.036 % TFA in ACN; Rt= 19.1 min) were combined and lyophilized, 
providing the TFA salt of the desired product (8 mg, 20 %). 1H-NMR (400 MHz, CD3OD) δ 
(ppm): 8.25 (2H, d, J=8.8), 8.17 (2H, d, J=8.4), 7.99 (2H, ddd, J=8.8, J=6.8, J=1.2), 7.56 
(2H, ddd, J=8.4, J=6.8, J=1.2), 5.72 (1H, d, J=3.6), 3.98 (1H, m), 3.71 (2H, t, J=6.8), 3.67-
3.60 (4H, m), 3.56 (1H, m), 3.52 (2H, m), 3.43-3.35 (5H, m), 3.21 (2H, q, J=7.2), 2.80 (2H, t, 
J=7.2), 2.55 (2H, t, J=7.2), 2.53 (2H, t, J=7.2), 2.10 (1H, dt, J=12.4, J=3.6), 1.98 (2H, q, 
J=6.8), 1.67 (1H, q, J=12.4), 1.61-1.49 (4H, m), 1.42-1.33 (4H, m); ESI-MS, positive mode: 
m/z 471.3 (calcd mass for C42H67N15O8S [M+2H]
2+: 470.75); HR ESI-MS, positive mode: m/z 
470.7520 (calcd mass for C42H67N15O8S [M+2H]
2+: 470.7509), m/z 314.1715 (calcd mass for 
C42H68N15O8S [M+3H]
3+: 314.1699). 
Acr2-NeaG4: 1,3-di-Boc-2-(trifluoromethylsulfonyl)guanidine (38 mg, 96 µmol) and Acr2-
Nea ligand8 (3.4 mg, 2.4 µmol) were dissolved in a 5:3 mixture of MeOH/CHCl3 (1 mL). 
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After addition of triethylamine (80 µL, 576 µmol), the reaction mixture was stirred for 4 days 
at RT under Ar. The mixture was concentrated in vacuo and the residue was dissolved in 
DCM (10 mL) and washed with a 0.1 M aqueous solution of citric acid (2 x 10 mL) and with 
brine (10 mL). The organic phase was taken up and dried over anhydrous MgSO4, filtered and 
concentrated in vacuo to dryness. Then, the crude was dissolved in a 1:1 mixture of 
TFA/DCM (1 mL) containing 2.5 % TIS. After stirring at RT for 2 h under Ar, the mixture 
was diluted with toluene (2 mL) and evaporated in vacuo. After two co-evaporations from 
toluene, the residue was dissolved in Milli-Q H2O (10 mL) and the aqueous phase was 
washed with DCM (2 x 10 mL), diethyl ether (10 mL) and lyophilized. The sulfoxide 
derivative of the product was isolated (1.35 µmol, 56 %) by reversed-phase HPLC (linear 
gradient from 10 to 40 % B in 30 min; A: 0.045 % TFA in H2O and B: 0.036 % TFA in ACN; 
Rt= 15.8 min). 
1H-NMR (400 MHz, D2O) δ (ppm): 8.37 (1H, d, J=9.2), 7.85 (1H, d, J=1.8), 
7.79 (1H, d, J=9.2), 7.73 (1H, d, J=2.6), 7.69 (1H, dd, J=9.2, J’=2.6), 7.51 (1H, dd, J=9.2, 
J’=1.8), 5.60 (1H, d, J=4.0), 4.20 (2H, t, J=6.4), 4.02 (3H, s), 3.98 (1H, m), 3.62-3.74 (4H, 
m), 3.46-3.59 (8H, m), 3.31 (2H, t, J=6.4), 2.78 (2H, t, J=7.2), 2.70 (2H, m), 2.26 (1H, m), 
2.13 (4H, m), 1.65-1.77 (5H, m), 1.40-1.59 (6H, m); ESI-MS, positive mode: m/z 990.9 (calcd 
mass for C43H69ClN15O8S [M+H]
+: 990.49); HR ESI-MS, positive mode: m/z 503.7464 (calcd 
mass for C43H70ClN15O9S [M+O+2H]
2+: 503.7440), m/z 336.1667 (calcd mass for 
C43H71ClN15O9S [M+O+3H]
3+: 336.1651). 
Acr2-Nea2G4: The guanidinylation of Acr2-Nea28 and the removal of the Boc protecting 
groups was carried out following the procedure described for the synthesis of Acr2-NeaG4 
from Acr2-Nea. After HPLC purification (linear gradient from 10 to 35 % B in 30 min; A: 
0.045 % TFA in H2O and B: 0.036 % TFA in ACN; Rt= 11.4 min), Acr2-Nea2G4 was 
obtained as a yellow solid (0.9 µmol, 25 %). 1H-NMR (500 MHz, CD3OD) δ (ppm): 8.25 
(1H, d, J=9.0), 7.74 (1H, s), 7.68 (1H, d, J=9.0), 7.60 (1H, s), 7.56 (1H, dd, J=9.0, J’=2), 
7.39 (1H, dd, J=9.0, J’=2), 5.52 (1H, d, J=3.5), 4.06 (3H, m), 3.90 (3H, s), 3.70 (1H, m), 
3.59-3.29 (10H, m), 3.31 (1H, m), 3.22 (2H, t, J=6.0), 2.69 (2H, t, J=6.0), 2.55 (2H, t, J=7.0), 
2.29 (2H, t, J=7.0), 2.14 (1H, m), 2.03 (2H, q, J=6.0), 1.55 (1H, m); MALDI-TOF-MS, 
positive mode: m/z 953.2; ESI-MS, positive mode: m/z 953.10 (calcd mass for 
C38H59ClN15O8S2 [M+H]
+: 952.38). 
 
Synthesis of oligoribonucleotides. Oligoribonucleotides were synthesized using 2’-O-tert-
butyldimethylsilyl (TBDMS) protection and following standard procedures (phosphite triester 
approach). The syntheses (1-µmol scale) were performed on an ABI 3400 DNA automatic 
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synthesizer according to the manufacturer’s synthesis protocol, with some modifications 
described here. For 5’-O-(dimethoxytrityl)-2’-O-(tert-butyldimethylsilyl (or 2’-O-methyl)-3’-
O-(2-cyanoethyl-N,N-diisopropyl)ribonucleoside phosphoramidite monomers, nucleobase-
protecting groups with increased base-sensitivity were used (phenoxyacetyl for adenine, 
acetyl for cytosine and 4-isopropylphenoxyacetyl for guanine). Benzylthio-1H-tetrazole (80-
fold excess, 0.3 M in anhydrous ACN) was used for the activation of phosphoramidite 
monomers (10-fold excess, 0.1 M in anhydrous ACN). Biotin- or fluoresceine 
phosphoramidite were incorporated in the last coupling cycle using tetrazole as activator. 
Oligoribonucleotides were cleaved from the solid support and deprotected following a 
stepwise protocol.23 First, a fast treatment with concentrated ammonium hydroxide and 
methylamine cleaved the oligoribonucleotide from the solid support and removed nucleobase- 
and phosphate-protecting groups. The second step involved treatment with triethylamine 
tris(hydrofluoride) to remove the 2’-O-TBDMS groups. Reversed-phase HPLC was used both 
for the analysis and purification of oligoribonucleotides: linear gradient from 0 to 30 % B in 
30 min for DMT-off sequences (A: 0.1 M aqueous NH4HCO3 and B: a 1:1 mixture of 0.1 M 
aqueous NH4HCO3 and ACN). Characterization was carried out by MALDI-TOF mass 
spectrometry (negative mode, THAP/CA matrix). Purity was also confirmed by PAGE.  
In all cases, the ends of the chains were modified with two 2’-O-methylribonucleosides 
(denoted with * label in the sequences, Scheme 1) to increase stability to ribonucleases.  
 
Evaluation of the interaction between RNA and ligands. A. UV-monitored melting 
experiments. Melting curves were recorded by cooling the samples from 90 ºC to 20 ºC at a 
constant rate of 0.5 ºC min-1 and measuring the absorbance at 260 nm as a function of 
temperature. Then, the reverse denaturation curve (20 ºC to 90 ºC) was recorded. All 
experiments were repeated at least three times until coincident Tm values were obtained. The 
error in Tm values was ± 0.2 ºC. The solutions were 1 µM both in RNA (wt, +3 or +14) and in 
ligands, in 10 mM sodium phosphate buffer pH 6.8, 100 mM NaCl and 0.1 mM Na2EDTA.  
B. Circular dichroism. Samples (3 µM both in RNA and in ligands) were prepared in the 
same buffer than in UV-monitored melting experiments. Spectra were recorded on a Jasco J-
720 spectropolarimeter with a thermoregulated cell holder and interfaced with a Neslab RP-
100 water bath, at 20 ºC. All CD spectra were baseline subtracted with a separately acquired 
buffer spectrum.  
C. UV-Vis titration experiments. A 50 µM solution of the ligand (Acr1-NeaG4 or Acr2-
NeaG4) and the corresponding amount of wt RNA (0, 0.02, 0.05, 0.1, 0.5, and 1 mol equiv) 
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was prepared in the previous buffer. The mixture was heated for 5 min to 90 ºC and left to 
slowly cool to RT. The absorption spectra were recorded at RT.  
D. Fluorescence binding assays. Fluorescence measurements were performed in 1-cm path-
length quartz cells on a QuantaMaster fluorometer (PTI) at 20 ºC, with an excitation slit width 
of 4.0 nm and an emission slit width of 5.2 nm. Upon excitation at 490 nm, the emission 
spectrum was recorded over a range between 500 and 550 nm until no changes in the 
fluorescence intensity were detected. All binding assays were performed in the melting curves 
buffer. 
For each experiment, the fluorescence spectrum of 120 µL buffer solution without RNA or 
ligand was first taken, to be used as the baseline. Following this buffer blank, the spectrum of 
a 0.25 µM solution of refolded RNA containing fluoresceine (120 µL) was recorded, and the 
baseline blank subtracted. Subsequent aliquots of 1 µL of an aqueous ligand solution 
(increasing in concentration from 0 to 0.75 mM, 0.0005-3000 mol equiv, depending on the 
ligand affinity) were added to the solution containing RNA, and the fluorescence spectrum 
was recorded after addition of each aliquot until the fluoresceine fluorescence signal at 517 
nm reached saturation (typically 5-10 min). Over the entire range of ligand concentrations, the 
emission maxima varied less than 1 nm. The total volume of the sample never changed more 
than 20 %. The full titration was repeated in the absence of labelled RNA to correct for the 
presence of the ligand’s fluorescence. These spectra were subtracted from each corresponding 
point of the labelled RNA titrations, and the resulting fluorescence intensity was corrected for 
dilution (F*V/V0).  
The emission fluorescence at 517 nm was normalized by dividing the difference between the 
observed fluorescence, F, and the initial fluorescence, F0, by the difference between the final 
fluorescence, Ff, and the initial fluorescence, F0. This normalized fluorescence intensity was 
plotted as a function of the logarithm of the total ligand concentration. Finally, nonlinear 
regression using a sigmoidal dose-response curve was performed with the software package 
GraphPad Prism 4 (GraphPad Software, San Diego, CA) to calculate the EC50 values. 
Experimental errors were less than or equal to ± 25% of each value. 
For competitive experiments, a tRNA from baker’s yeast (S. cerevisiae) was purchased from 
Sigma. Stock solutions of tRNAmix were quantified using an average extinction coefficient of 
9.640 cm-1 per base.19b The fluorescence binding assays were carried out as described above 
with the exception that a 30-fold excess (base) of the tRNAmix was added to the refolded 
fluoresceine-labelled RNA (or to the buffer for the titration without target RNA). 
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F. NMR Spectroscopy of RNA-ligand complexes. NMR spectra were acquired in a Bruker 
Advance spectrometer operating at 600 MHz and equipped with a cryoprobe. Samples of the 
complexes were prepared by mixing the appropriate amounts of RNA and ligand and 
performing an annealing protocol consisting of heating to 90ºC for 3 min, followed by snap 
cooling on ice for 20 min. Samples were dissolved in a 10 mM sodium phosphate, pH 6.8, in 
a 9:1 H2O/D2O mixture and NMR spectra were recorded at 5ºC to reduce the exchange with 
water. Water suppression was achieved by using an excitation sculpting sequence (zgesgp).  
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Text and figure for the Table of Contents 
Guanidinylation of the aminoglycoside moiety of ligands for the stem-loop secondary 
structure of Tau pre-mRNA modifies their RNA-binding properties.  
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